NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/25/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization27.61 mln
Float5.08 mln
Earnings Date11/19/2026
Piotroski F-Score
5
/ 9
Neutral
Relative Strength
88
/ 100
Strongly outperforming
Debt / Equity
-0.06
Negative equity
ROE
-110
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
Evaxion A/S is a Danish biotech company that uses artificial intelligence to develop vaccines against cancer and infectious diseases. Its cancer vaccine pipeline includes treatments for advanced melanoma, solid tumors, and acute myeloid leukemia, with some candidates already in clinical trials. The company is also working on early-stage vaccines targeting bacterial infections and cytomegalovirus. Founded in 2008 and headquartered in Hørsholm, Denmark, Evaxion trades under a name it adopted in May 2025, having previously operated as Evaxion Biotech A/S.
